Osteoporosis-related health-care costs are lower for postmenopausal women prescribed bisphosphonates-if they comply with therapy. That is the conclusion of a retrospective analysis of prescription and treatment data presented at this year's NAMS meeting.
Osteoporosis-related health-care costs are lower for postmenopausal women prescribed bisphosphonates-if they comply with therapy. That is the conclusion of a retrospective analysis of prescription and treatment data presented at this year's NAMS meeting.
Data collected by Medstat and Medicare from more than 32,000 women aged 45 or older who filled a prescription for daily or weekly alendronate or risedronate were assessed. At the end of the 3-year study period, 37% of the women got their refills (compliant) and 21% had no gaps between bisphosphonate refills (persistence).
Mean costs of inpatient admissions were lower for those who were compliant and persistent-$10,653 and $9,846-versus noncompliant and nonpersistent-$14,074 and $13,601. Total mean health-care costs were $17,840 for women with on-time refills and $16,521 for women who took medication consistently, compared with $22,906 for those who missed refills and $22,219 for medication skippers.
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More